Advertisement

Clinical Rheumatology

, 28:421 | Cite as

Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha

  • Osman Elbek
  • Meral Uyar
  • Neriman Aydın
  • Şermin Börekçi
  • Nazan Bayram
  • Hasan Bayram
  • Öner Dikensoy
Original Article

Abstract

Drugs which antagonize tumor necrosis factor alpha (TNF-α) are known to increase the risk of tuberculosis. We aimed to evaluate the risk of tuberculosis in patients treated with anti-TNF-α, in Turkey. Two hundred and forty patients receiving anti-TNF-α, from December 2005 to December 2007, were included in the study. All participants provided a history and underwent a physical examination, a chest X-ray, and a tuberculin skin test. Isoniazid treatment was initiated in those patients with a latent infection, and they were followed up at 2-month intervals. A Bacillus Calmette-Guerin (BCG) scar was present in 184 patients (77.6%). The mean tuberculin skin test induration of patients on admission was 10.7 ± 7.0 mm. Male gender and the presence of a BCG scar were predictors of a higher tuberculin skin test result (P < 0.05), while there was no significant effect of age on the tuberculin skin test (P > 0.05). Of the 240 subjects, 229 (95.4%) received methotrexate or corticosteroid treatment prior to anti-TNF-α therapy. Isoniazid treatment preceded anti-TNF-α administration in 185 (77.1%) of the 240 patients. Two patients developed tuberculosis (incidence 833/100,000). There was no correlation between initial and 12-month tuberculin skin test results (P > 0.05). Tuberculin skin test conversion was detected in five subjects during the 12-month follow-up; however, none developed active tuberculosis. One patient developed a drug reaction secondary to etanercept, and another demonstrated hepatotoxicity due to isoniazid. This study shows that anti-TNF-α therapy increases the risk of tuberculosis, despite treatment of latent infection.

Keywords

Adverse event Screening TNF alpha blocking agent Tuberculosis 

Notes

Disclosures

None.

References

  1. 1.
    Cho H, Lasco TM, Allen SS et al (2005) Recombinant guinea pig tumor necrosis factor alpha stimulates the expression of interleukin-12 and the inhibition of Mycobacterium tuberculosis growth in macrophages. Infect Immun 73:1367–1376PubMedCrossRefGoogle Scholar
  2. 2.
    Mutlu GM, Mutlu EA, Bellmeyer A et al (2006) Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy. Am J Med 119:639–646PubMedCrossRefGoogle Scholar
  3. 3.
    Vordermeier HM (1995) T-cell recognition of mycobacterial antigens. Eur Respir J Suppl 20(Suppl):657–667Google Scholar
  4. 4.
    Flynn JL, Goldstein MM, Chan J et al (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561–572PubMedCrossRefGoogle Scholar
  5. 5.
    Stenger S (2005) Immunological control of tuberculosis: role of tumour necrosis factor and more. Ann Rheum Dis 64(Suppl 4):24–28Google Scholar
  6. 6.
    Engele M, Stössel E, Castiglione K et al (2002) Induction of TNF in human alveolar macrophages as a potential evasion mechanism of virulent Mycobacterium tuberculosis. J Immunol 168:1328–1337PubMedGoogle Scholar
  7. 7.
    Schiff MH, Burmester GR, Kent JD et al (2006) Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann Rheum Dis 65:889–894PubMedCrossRefGoogle Scholar
  8. 8.
    Kıter G, Uçan ES (2001) Prevention of tuberculosis. Toraks 2:85–90Google Scholar
  9. 9.
    WHO Global Health Atlas (2007) Turkey. http://www.who.int/GlobalAtlas/predefinedReports/TB/index.asp?strSelectedCountry=tur Accessed 20 Aug 2007
  10. 10.
    Ozsahin SL, Akkurt I, Ozdemir L et al (2006) Are official reports sufficient? Official registration rates of patients with tuberculosis in Sivas, Middle Anatolia. Public Health 120:434–440PubMedCrossRefGoogle Scholar
  11. 11.
    Şakar A, Göktalay T, Dağyıldızı L et al (2003) A tuberculosis screening among school children in Manisa Province. Toraks 4:38–42Google Scholar
  12. 12.
    Tanrıkulu Ç, Abakay A, Abakay Ö et al (2006) Tuberculosis screening results made at primary schools in Cizre. Tuberk Toraks 54:336–340PubMedGoogle Scholar
  13. 13.
    Bozkurt Aİ, Bozkurt N (2001) Gaziantep kent merkezi’nde beş yaşından küçük çocuklarda BCG aşılama oranları. Anadolu Tıp Dergisi 3:163–167Google Scholar
  14. 14.
    Lasco TM, Cassone L, Kamohara H et al (2005) Evaluating the role of tumor necrosis factor-alpha in experimental pulmonary tuberculosis in the guinea pig. Tuberculosis (Edinb) 85:245–258CrossRefGoogle Scholar
  15. 15.
    Keane J, Gershon S, Wise RP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104PubMedCrossRefGoogle Scholar
  16. 16.
    Gardam MA, Keystone EC, Menzies R et al (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148–155PubMedCrossRefGoogle Scholar
  17. 17.
    Toussirot E, Wendling D (2004) The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother 5:581–594PubMedCrossRefGoogle Scholar
  18. 18.
    Winthrop KL (2006) Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2:602–610PubMedCrossRefGoogle Scholar
  19. 19.
    Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V et al (2005) Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 52:1766–1772PubMedCrossRefGoogle Scholar
  20. 20.
    Provenzano G, Ferrante MC, Simon G (2005) TB screening and anti-TNF alpha treatment. Thorax 60:613PubMedCrossRefGoogle Scholar
  21. 21.
    Bargman C (2004) TNF inhibitors and tuberculosis. Am J Nurs 104:15–16PubMedGoogle Scholar
  22. 22.
    Roberts L, McColl GJ (2004) Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Intern Med J 34:687–693PubMedCrossRefGoogle Scholar
  23. 23.
    Gomez-Reino JJ, Carmona L, Valverde VR et al (2003) Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 48:2122–2127PubMedCrossRefGoogle Scholar
  24. 24.
    Askling J, Fored CM, Brandt L et al (2005) Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 52:1986–1992PubMedCrossRefGoogle Scholar
  25. 25.
    Dunlop H (2004) Infliximab (Remicade) and etanercept (Enbrel): serious infections and tuberculosis. CMAJ 171:992–993PubMedGoogle Scholar
  26. 26.
    Imaizumi K, Sugishita M, Usui M et al (2006) Pulmonary infectious complications associated with anti-TNF alpha therapy (infliximab) for rheumatoid arthritis. Intern Med 45:685–688PubMedCrossRefGoogle Scholar
  27. 27.
    Hanta I, Ozbek S, Kuleci S et al (2008) The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients. Clin Rheumatol 27:1083–1086PubMedCrossRefGoogle Scholar
  28. 28.
    Desai SB, Furst DE (2006) Problems encountered during anti-tumour necrosis factor therapy. Best Pract Res Clin Rheumatol 20:757–790PubMedCrossRefGoogle Scholar
  29. 29.
    Wallis RS, Broder MS, Wong JY et al (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261–1265PubMedCrossRefGoogle Scholar
  30. 30.
    British Thoracic Society Standards of Care Committee (2005) BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 60:800–805CrossRefGoogle Scholar
  31. 31.
    Joven BE, Almodovar R, Galindo M et al (2006) Does anti-tumour necrosis factor alpha treatment modify the tuberculin PPD response? Ann Rheum Dis 65:699PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2008

Authors and Affiliations

  • Osman Elbek
    • 1
  • Meral Uyar
    • 1
  • Neriman Aydın
    • 2
  • Şermin Börekçi
    • 1
  • Nazan Bayram
    • 1
  • Hasan Bayram
    • 1
  • Öner Dikensoy
    • 1
  1. 1.Department of Pulmonary Diseases, Faculty of MedicineUniversity of GaziantepGaziantepTurkey
  2. 2.Department of Public Health, Faculty of MedicineUniversity of GaziantepGaziantepTurkey

Personalised recommendations